After substantial weight loss on a very-low-carbohydrate diet, participants who switched to a diet rich in refined starch ...

Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy ...

Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy Initial data is expected in 2027 WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWI ...

Akebia Therapeutics, Inc. ( AKBA) announced that the first patient has been dosed in its Phase 2 basket trial evaluating ebribafusp for rare complement-mediated kidney diseases, including IgA ...

As of Tuesday, September 15, Ionis Pharmaceuticals, Inc.’s IONS share price has dipped by 5.02%, which has investors ...

Low-carbohydrate diets are one of the most popular options for losing weight, with data suggesting 7 percent of Americans ...

Cholangiopathies comprise a heterogeneous group of chronic liver diseases characterised by progressive bile duct injury, ...

The ocean has always been a domain of strategic competition — but today’s naval battles are fought on two fronts ...

Explore the preclinical research catching our eye in September 2026, from siRNA and in vivo CRISPR to targeted protein ...

Launched in 2025 with the support of a grant from the national LearningWell Coalition, the 4D Faculty Teaching Fellows serve ...

Environmental quality is a personal health issue. And it should shape how physicians, communities, and policymakers respond.

Operators delivering BEAD-funded projects cannot control every permitting process. But they can influence how much new infrastructure actually needs to be built. With 86,402 potential permitting-relat ...